



Faculty of Pharmacy



El-Minia University

## CURRICULUM VITAE

### Personal Information...

- ☒ **Name:** Maiiada Hassan Nazmy
- ☒ **Date Of Birth:** 14<sup>th</sup>, April, 1981
- ☒ **Nationality:** Egyptian
- ☒ **E-Mail:** [mnazmy@yahoo.com](mailto:mnazmy@yahoo.com)

### Academic Qualifications...

#### 1. **B.Sc Degree :** In Pharmaceutical Sciences

- ✦ **Institute:** Faculty of Pharmacy, El-Minia University
- ✦ **Date:** May 2002
- ✦ **Grade:** Excellent with honor (92.92%)

#### 2. **M.Sc Degree:** In Biochemistry,

- ✦ **Institute:** Faculty of Pharmacy, El-Minia University
- ✦ **Date:** October 2005
- ✦ **Title:** "Effect of (B-Alanyl-1-Methyl-L-Histidine) along with zinc against gamma radiation -induced hepatotoxicity in rats ".

#### 3. **PhD Degree:** In Biochemistry,

- ✦ **Institute:** Faculty of Pharmacy, El-Minia University
- ✦ **Date:** January 2010
- ✦ **Title:** "An Aldose Reductase Inhibitor (ARI) And Diallyl Sulfide (DAS) as a chemopreventive and chemosensitizing combination for hepatocellular carcinoma in experimental diabetic models".

## *Professional Qualifications...*

### ☒ **Present Employment:**

- ✚ Lecturer of Biochemistry, Faculty of Pharmacy, El-Minia University (From February 2010).

### ☒ **Previous Employments:**

- ✚ Assistant lecturer of Biochemistry, Faculty of Pharmacy, El-Minia University (From November 2005).
- ✚ Demonstrator of Biochemistry, Faculty of Pharmacy, El-Minia University (From October 2002).

## *Research Interests...*

- ✚ Our main focus of research is related to liver diseases, including Non-alcoholic steatohepatitis (NASH), hepatitis C virus (HCV) and hepatocellular carcinoma (HCC), which are regarded as the most serious health problems in Egypt and worldwide.
- ✚ Study the impact of possible risk factors (i.e. Diabetes Mellitus) on the outcome and severity of hepatic disease.
- ✚ Establish and compare various experimental models for hepatocellular carcinoma.
- ✚ Reveal major molecular mechanisms that may be involved in the progression of these diseases.
- ✚ Identify possible hepatoprotective agents that may improve outcome and prognosis in these diseases.
- ✚ Suggest novel biomarkers which may increase sensitivity of classical biomarkers of hepatic injury.

Signature

*Maiiada Hassan Nazmy*